A Double-blind, Placebo-controled, Crossover Study To Evaluate the Efficacy, Safety and Tolerability of Inhaled ASM8-003 in Subjects With Mild Allergic Asthma.
Latest Information Update: 29 Feb 2024
At a glance
- Drugs ASM 8 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Pharmaxis; Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 11 Sep 2007 Status changed from in progress to completed.
- 14 Sep 2006 New trial record.